These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11465799)

  • 1. Reversible encephalopathy associated with tacrolimus in pediatric renal transplants.
    Parvex P; Pinsk M; Bell LE; O'Gorman AM; Patenaude YG; Gupta IR
    Pediatr Nephrol; 2001 Jul; 16(7):537-42. PubMed ID: 11465799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anorexia nervosa in a pediatric renal transplant recipient and its reversal with cyclosporine.
    Okechuku G; Boulos AK; Herman L; Upadhyay K
    Pediatr Transplant; 2015 May; 19(3):E78-82. PubMed ID: 25661468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus-induced encephalopathy and polyneuropathy in a renal transplant recipient.
    Wu G; Weng FL; Balaraman V
    BMJ Case Rep; 2013 Dec; 2013():. PubMed ID: 24311415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posterior reversible encephalopathy syndrome in children: its high prevalence and more extensive imaging findings.
    Ishikura K; Ikeda M; Hamasaki Y; Hataya H; Shishido S; Asanuma H; Nishimura G; Hiramoto R; Honda M
    Am J Kidney Dis; 2006 Aug; 48(2):231-8. PubMed ID: 16860188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mismatch between MRI lesions and SPECT hypoperfusion in tacrolimus-related encephalopathy.
    Shijo T; Nishiyama S; Mukai Y; Tateyama M; Kuroda H; Aoki M
    J Neurol Sci; 2016 Aug; 367():308-10. PubMed ID: 27423609
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation.
    Barone GW; Ketel BL; Abul-Ezz SR; Lightfoot ML
    JOP; 2002 Mar; 3(2):49-53. PubMed ID: 11884766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
    Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin inhibitors in pediatric renal transplant recipients.
    Filler G
    Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients.
    Akutsu N; Iwashita C; Maruyama M; Ootsuki K; Ito T; Saigo K; Kenmochi T
    Transplant Proc; 2008 Sep; 40(7):2416-8. PubMed ID: 18790253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients.
    Furth S; Neu A; Colombani P; Plotnick L; Turner ME; Fivush B
    Pediatr Nephrol; 1996 Feb; 10(1):64-6. PubMed ID: 8611359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitors in renal transplantation: what is the best option?
    Tanabe K
    Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus-associated mania with psychotic symptoms in a child after renal transplant.
    Gupta P; Singh J; Mahapatra A; Sharan P
    Natl Med J India; 2018; 31(5):281-282. PubMed ID: 31267993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus (FK506)-induced severe and late encephalopathy in a renal transplant recipient.
    Grimbert P; Azema C; Pastural M; Dhamane D; Remy P; Salomon L; Schortgen F; Baron C; Lang P
    Nephrol Dial Transplant; 1999 Oct; 14(10):2489-91. PubMed ID: 10528682
    [No Abstract]   [Full Text] [Related]  

  • 14. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation.
    Wong R; Beguelin GZ; de Lima M; Giralt SA; Hosing C; Ippoliti C; Forman AD; Kumar AJ; Champlin R; Couriel D
    Br J Haematol; 2003 Jul; 122(1):128-34. PubMed ID: 12823354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunosuppressive-associated encephalopathy in bone marrow transplant recipients].
    Ohta K; Yoritaka A; Sakamaki H; Kishida S;
    No To Shinkei; 2004 May; 56(5):395-401. PubMed ID: 15279197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation.
    Morales JM
    Kidney Int Suppl; 2002 Dec; (82):S81-7. PubMed ID: 12410861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation.
    Toledo Perdomo K; Navarro Cabello MD; Pérez Sáez MJ; Ramos Pérez MJ; Agüera Morales ML; Aljama García P
    J Nephrol; 2012; 25(5):839-42. PubMed ID: 22252846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.